Open AccessApathy symptoms induced by low‐dose venlafaxine: Two cases
Author(s) -
Sato Shinji,
Sodeyama Noriko,
Matsuzaki Asaki,
Shiratori Yuki
Publication year - 2020
Publication title -
neuropsychopharmacology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.661
H-Index - 13
ISSN - 2574-173X
DOI - 10.1002/npr2.12104
Subject(s) - apathy , venlafaxine , adverse effect , major depressive disorder , psychiatry , psychology , medicine , depression (economics) , 5 ht receptor , serotonin , antidepressant , anxiety , cognition , receptor , macroeconomics , economics
Recent guidelines regarding pharmacological interventions for major depressive disorder (MDD) recommend first using serotonin (5HT) selective reuptake inhibitors (SSRIs) or 5HT and norepinephrine (NE) reuptake inhibitors (SNRIs). Although SSRIs and SNRIs are effective and well‐tolerated, apathy occurs as an adverse effect in some SSRIs‐treated patients. Because apathy would be associated with the 5HT pathway, if a patient exhibits apathy symptoms under SSRIs treatment, a clinical strategy has been to change the SSRIs to treatment with an SNRIs. Here, I report two cases in which low‐dose venlafaxine, an SNRIs, induced apathy symptoms.